Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Deutsche Boerse AG
  5. SYNLAB AG
  6. News
  7. Summary
    SYAB   DE000A2TSL71

SYNLAB AG

(SYAB)
  Report
Real-time Estimate Quote. Real-time Estimate Tradegate - 09/21 03:58:00 pm
20.7 EUR   +2.32%
09/17SYNLAB : Deutsche Bank keeps its Buy rating
MD
09/10SYNLAB : Barclays sticks Neutral
MD
09/06SYNLAB : Goldman Sachs gives a Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

PRESS RELEASE : SYNLAB: SYNLAB and AXA Partners enter a partnership to enhance safe travel this summer

07/29/2021 | 04:02am EDT
DGAP-News: SYNLAB AG / Key word(s): Alliance 
SYNLAB: SYNLAB and AXA Partners enter a partnership to enhance safe travel this summer 
2021-07-29 / 10:01 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
  . SYNLAB supports AXA Partners in enabling customers and employees to resume travel safely 
  . SYNLAB and AXA Partners leverage SYNLAB's broad international laboratory network and medical expertise to provide 
    safe and easy COVID-19 testing, ensuring delivery of PCR test results within 24 to 48 hours 
SYNLAB, Europe's leading medical diagnostic services provider, and AXA Partners enter a partnership to facilitate safe 
and easy travelling for customers and employees. AXA Partners is part of the AXA Group, a global leader in insurance 
and asset management, with more than 9,000 employees serving customers worldwide. 
Leveraging SYNLAB's broad laboratory network, AXA Partners' customers and employees are being offered comprehensive 
COVID-19 testing services in more than 10 European countries, including Spain, Portugal and France and covering around 
900 testing centres. The partnership may be extended to include further countries. 
PCR tests are considered gold standard for COVID-19 testing, providing the highest possible sensitivity and 
specificity. A negative PCR test result ensures that customers and employees are not infected with SARS-CoV-2, which 
helps to protect their environment. In addition, it can also facilitate their on-/homeward journey and border crossing. 
Besides PCR testing, the partnership also includes antigen tests and self-administrated test kits, if country 
regulation permits. 
AXA Partners' customers and employees can find SYNLAB laboratories and sample collection points through AXA Partners' 
vetted medical network, whereby SYNLAB - as the preferred partner in testing for COVID-19 - is ranked first on search 
results. 
Mathieu Floreani, CEO of SYNLAB, says: "At a time when people around the world want to resume travel and different 
variants of the SARS-CoV-2 virus are spreading, testing remains crucial. We are pleased that AXA Partners has chosen 
SYNLAB as the preferred provider for testing. Together, we will make travel as safe as possible for their customers and 
employees." 
Julia d'Astorg, Chief International Medical Services Officer, AXA Partners: "We at AXA Partners continually strive to 
provide a best-in-class health services to our customers. This means that when looking for a Partner, we always ensure 
that their standard of service, ethos and ability to promptly innovate are aligned with ours. We are very happy to have 
found that in SYNLAB." 
For more information: 
Media contact:                         +49 (0) 151 46693856 
Diana Tabor, FTI Consulting            diana.tabor@fticonsulting.com 
Investor contact:                      +49 (0) 170 118 3753 
Mark Reinhard, SYNLAB                  Mark.Reinhard@synlab.com About SYNLAB   . SYNLAB, (ISIN: DE000A2TSL71, SYMBOL: SYAB) is the largest European clinical laboratory and medical diagnostic 

services company and offers a full range of innovative and reliable medical diagnostics for patients, practising

doctors, clinics and the pharmaceutical industry. . Providing the leading level of service within the industry, SYNLAB is the partner of choice for diagnostics in

human and veterinary medicine. The Group continuously innovates medical diagnostic services for the benefit of

patients and customers. . SYNLAB operates in 36 countries across four continents and holds leading positions in most markets. More than

20,000 employees, including over 1,200 medical experts, as well as a large number of other specialists such as

biologists, chemists and laboratory technicians, contribute every day to the Group's worldwide success. SYNLAB

carries out 500 million laboratory tests per year and achieved revenues of EUR 2.6 billion in 2020. . More information can be found on www.synlab.com -----------------------------------------------------------------------------------------------------------------------

2021-07-29 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      SYNLAB AG 
              Moosacher Straße 88 
              80809 Munich 
              Germany 
Phone:        +49 1701183753 
E-mail:       ir@synlab.com 
Internet:     www.synlab.com/ 
ISIN:         DE000A2TSL71 
WKN:          A2TSL7 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1222522 
 
End of News   DGAP News Service 
=------------ 

1222522 2021-07-29

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1222522&application_name=news 
 

(END) Dow Jones Newswires

July 29, 2021 04:01 ET (08:01 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
AXA 1.14% 22.625 Real-time Quote.14.65%
SYNLAB AG 3.26% 20.89 Delayed Quote.0.00%
All news about SYNLAB AG
09/17SYNLAB : Deutsche Bank keeps its Buy rating
MD
09/10SYNLAB : Barclays sticks Neutral
MD
09/06SYNLAB : Goldman Sachs gives a Buy rating
MD
08/19FAULTY LAB TESTS : Hundreds of drug-driving convictions could be quashed
AQ
08/12PRESS RELEASE : SYNLAB delivers outstanding -3-
DJ
08/12PRESS RELEASE : SYNLAB delivers outstanding -2-
DJ
08/12PRESS RELEASE : SYNLAB delivers outstanding financial and operational results in Q2 and H1..
DJ
08/12SYNLAB : delivers outstanding financial and operational results in Q2 and H1 2021
EQ
08/12SYNLAB AG Reports Unaudited Consolidated Earnings Results for the Second Quarter and Fi..
CI
08/12SYNLAB AG Revises Earnings Guidance for the Year 2021
CI
More news
Analyst Recommendations on SYNLAB AG
More recommendations
Financials
Sales 2021 3 441 M 4 034 M 4 034 M
Net income 2021 500 M 586 M 586 M
Net Debt 2021 1 646 M 1 929 M 1 929 M
P/E ratio 2021 9,90x
Yield 2021 2,55%
Capitalization 4 642 M 5 440 M 5 442 M
EV / Sales 2021 1,83x
EV / Sales 2022 2,18x
Nbr of Employees 23 000
Free-Float 75,7%
Chart SYNLAB AG
Duration : Period :
SYNLAB AG Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Last Close Price 20,89 €
Average target price 23,29 €
Spread / Average Target 11,5%
EPS Revisions
Managers and Directors
Mathieu Olivier Floreani Chairman-Management Board & CEO
Sami Badarani Chief Financial Officer & Finance Director
David Raymond Ebsworth Chairman-Supervisory Board
Valor Garcia Santiago Chief Medical Officer
Henrik Andreasen Chief Information Officer
Sector and Competitors
1st jan.Capi. (M$)
SYNLAB AG0.00%5 276
SONIC HEALTHCARE LIMITED29.24%14 499
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.-24.16%6 952
NEOGENOMICS, INC.-12.70%5 780
DR. LAL PATHLABS LIMITED71.40%4 422
HEALIUS LIMITED32.17%2 159